STATE-OF-THE-ART PAPER
Cardiovascular Protection Using Beta-BlockersA Critical Review of the Evidence
Sripal Bangalore, MD, MHA*,
Franz H. Messerli, MD*,1,*,
John B. Kostis, MD ,2 and
Carl J. Pepine, MD ,3
* St. Luke’s-Roosevelt Hospital and Columbia University, New York, New York
University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, New Jersey
University of Florida College of Medicine, Gainesville, Florida.
Manuscript received February 14, 2007;
revised manuscript received April 13, 2007,
accepted April 30, 2007.
* Reprint requests and correspondence: Dr. Franz H. Messerli, Director, Hypertension Program, Division of Cardiology, St. Luke’s-Roosevelt Hospital, Columbia University College of Physicians and Surgeons, 1000 10th Avenue, Suite 3B-30, New York, New York 10019. (Email: fmesserl{at}chpnet.org).
For more than 3 decades, beta-blockers have been widely used in the treatment of hypertension and are still recommended as first-line agents by national and international guidelines. Recent meta-analyses indicate that, in patients with uncomplicated hypertension, compared with other antihypertensive agents, first-line therapy with beta-blockers was associated with an increased risk of stroke, especially in the elderly cohort with no benefit for the end points of all-cause mortality, cardiovascular morbidity, and mortality. In this review, we critically analyze the evidence supporting the use of beta-blockers in patients with hypertension and evaluate evidence for its role in other indications. The review of the currently available literature shows that in patients with uncomplicated hypertension, there is a paucity of data or absence of evidence to support use of beta-blockers as monotherapy or as first-line agents. Given the increased risk of stroke, their "pseudo-antihypertensive" efficacy (failure to lower central aortic pressure), lack of effect on regression of target end organ effects like left ventricular hypertrophy and endothelial dysfunction, and numerous adverse effects, the risk benefit ratio for beta-blockers is not acceptable for this indication. However, beta-blockers remain very efficacious agents for the treatment of heart failure, certain types of arrhythmia, hypertropic obstructive cardiomyopathy, and in patients with prior myocardial infarction.
|
Abbreviations and Acronyms
| | ACC/AHA = American College of Cardiology/American Heart Association | | CI = confidence interval | | HR = hazard ratio | | JNC = Joint National Committee | | LVH = left ventricular hypertrophy | | MI = myocardial infarction | | NNH = number needed to harm | | RAAS = renin angiotensin aldosterone system |
|
This article has been cited by other articles:
|
|
|
|
 
D. W. Kemp and J. N. Brown
Recent Advances in Pharmacotherapy
Journal of Pharmacy Practice,
October 1, 2009;
22(5):
446 - 466.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. J. Lavie, F. H. Messerli, and R. V. Milani
Beta-blockers as first-line antihypertensive therapy the crumbling continues.
J. Am. Coll. Cardiol.,
September 22, 2009;
54(13):
1162 - 1164.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Klapholz
{beta}-Blocker Use for the Stages of Heart Failure
Mayo Clin. Proc.,
August 1, 2009;
84(8):
718 - 729.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Marshall, P. H. Lin, T. T. Huynh, and P. Kougias
How Optimal is the Medical Management of Patients Prior to Major Reconstructive Vascular Surgery? The Results of a Cross-sectional Study
Vascular and Endovascular Surgery,
June 1, 2009;
43(3):
238 - 243.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. M. Cooper-DeHoff, M. A. Pacanowski, and C. J. Pepine
Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.
J. Am. Coll. Cardiol.,
February 3, 2009;
53(5 Suppl):
S28 - S34.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Nagayama, S. Hsu, M. Zhang, N. Koitabashi, D. Bedja, K. L. Gabrielson, E. Takimoto, and D. A. Kass
Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload.
J. Am. Coll. Cardiol.,
January 13, 2009;
53(2):
207 - 215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. Elias and G. A. Dore
Brain Indices Predict Blood Pressure Control: Aging Brains and New Predictions
Hypertension,
December 1, 2008;
52(6):
1014 - 1015.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Kaplan
Beta-Blockers in Hypertension: Adding Insult to Injury
J. Am. Coll. Cardiol.,
October 28, 2008;
52(18):
1490 - 1491.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bangalore, D. Wild, S. Parkar, M. Kukin, and F. H. Messerli
Beta-Blockers for Primary Prevention of Heart Failure in Patients With Hypertension: Insights From a Meta-Analysis
J. Am. Coll. Cardiol.,
September 23, 2008;
52(13):
1062 - 1072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Gray and U. A. Ndefo
Nebivolol: A new antihypertensive agent
Am. J. Health Syst. Pharm.,
June 15, 2008;
65(12):
1125 - 1133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. H. Messerli, S. Bangalore, and S. Julius
Risk/Benefit Assessment of {beta}-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension
Circulation,
May 20, 2008;
117(20):
2706 - 2715.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Williams
The Year in Hypertension
J. Am. Coll. Cardiol.,
May 6, 2008;
51(18):
1803 - 1817.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. London
Quo Vadis, Perioperative Beta Blockade? Are You "POISE'd" on the Brink?
Anesth. Analg.,
April 1, 2008;
106(4):
1025 - 1030.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Giles, G. L. Bakris, and M. A. Weber
Beta-blocker therapy in hypertension: a need to pause and reflect.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
516 - 517.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. H. Messerli and S. Bangalore
Reply.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
517 - 518.
[Full Text]
[PDF]
|
|
|
|
